An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis

Yakir Segev, Ofer Gemer, Limor Helpman, Nasreen Hag-Yahia, Ram Eitan, Oded Raban, Zvi Vaknin, Alon Ben-Arie, Amnon Amit, Tally Levy, Ahmed Namazov, Michael Voldarsky, Inbar Ben Shachar, Ilan Atlas, Ilan Bruchim, Ofer Lavie

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objective: To assess whether statin use by endometrial cancer patients was associated with a survival advantage. Methods: A retrospective chart review study, by the Israeli Gynecologic Oncology Group, of consecutive endometrial cancer patients who underwent surgery in one of 11 medical centers between 2002 and 2014. Clinical and pathological reports, and measures of survival were compared between statin users and nonusers. Kaplan-Meier and Cox proportional hazard models were used to assess the effect of using statins on survival measures. Results: Over a mean follow-up period of 6.2 years (range, 1–12 years) for 2017 endometrial cancer patients with complete data, 663 (32.8%) used statins prior to diagnosis and 1354 (67.1%) did not. No statistically significant differences between the groups were observed for most demographic and clinical characteristics. There was no difference between statin users and nonusers in 5-year recurrence-free survival (82% vs 83%; P=0.508), disease-specific survival (86% vs 84%; P=0.549), or overall survival (77% vs 75%; P=0.901). Conclusions: In this large cohort of patients with endometrial cancer, no significant associations were found between use of statins and endometrial cancer survival.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalInternational Journal of Gynecology and Obstetrics
Issue number1
StatePublished - 1 Jan 2020

Bibliographical note

Publisher Copyright:
© 2019 International Federation of Gynecology and Obstetrics


  • Endometrial cancer
  • Israeli Gynecologic Study Group
  • Statins
  • Survival


Dive into the research topics of 'An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis'. Together they form a unique fingerprint.

Cite this